Adicet Bio (ACET) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with the CFO appointed as Secretary to record minutes.
Stockholders were welcomed, and the meeting was confirmed to be held in accordance with bylaws and Delaware law.
Directors, executive team, audit firm, and outside counsel were introduced.
Rules of conduct and voting eligibility were explained, with instructions for submitting questions and voting.
Corporate governance
An independent Inspector of Election was appointed to oversee and tabulate voting results.
Quorum was established with 6,746,169 shares represented out of 9,598,201 entitled to vote.
Board and executive committee updates
Three nominees for Class II directors were presented for election to serve three-year terms.
No stockholder nominations for directors were received; nominations were closed.
Latest events from Adicet Bio
- Major data readouts in LN/SLE and new pipeline updates signal pivotal progress for off-the-shelf cell therapies.ACET
Canaccord Genuity's 46th Annual Growth Conference - Prula-cel enables steroid-free remissions in autoimmune disease; ADI-212 advances in prostate cancer.ACET
Investor presentation - Q2 2026 net loss was $21.4M; cash runway and key clinical milestones extend into H2 2027.ACET
Q2 2026 - Major mid-year data update for prula-cel in autoimmune diseases and new solid tumor program advancing.ACET
Jefferies Global Healthcare Conference 2026 - Prula-cel delivers durable remission and immune reset in autoimmune disease, while ADI-212 advances for mCRPC.ACET
Investor presentation - Net loss narrowed, cash runway extends into H2 2027 as pivotal trials advance and risks persist.ACET
Q1 2026 - Vote on directors, executive pay, and auditor ratification at the June 2026 annual meeting.ACET
Proxy filing - Virtual annual meeting to elect directors, approve pay, and ratify auditor, with robust governance.ACET
Proxy filing - Prula-cel delivers steroid-free remissions and immune reset in autoimmune disease patients.ACET
Investor presentation